A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT04702568 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

19

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Paroxysmal Nocturnal Hemoglobinuria
PNH

Interventions

DRUG: BCX9930
DRUG: Eculizumab
DRUG: Ravulizumab

Sponsor

BioCryst Pharmaceuticals